On 29 June 2023, Aker BioMarine ASA ("Aker BioMarine" or the "Company")
announced a change to its group financial reporting and legal entity structure,
separating into business units (1) Feed Ingredients; (2) Human Health
Ingredients; (3) Consumer Health Ingredients; and (4) Emerging Businesses. As of
1 January 2024, the financial and legal reorganization has been completed and
the business units are now operational as separate business units.  

Based on external interest for the Feed Ingredients business, the Company has
decided to initiate a process to explore strategic alternatives for that
business unit.

Aker BioMarine Feed Ingredients is the world's largest krill harvester and
producer of krill meal. Krill meal is a premium marine ingredient used in
aquaculture feed, pet food and for extraction of krill oil for human
consumption. Feed Ingredients owns and operates three specialized harvesting
vessels and a support vessel. Production takes place in Antarctica utilizing an
efficient and sustainable harvesting technology.

Feed Ingredients has experienced strong growth over the recent years and
realized FY23 adjusted revenues of approximately USD 156 million and an adjusted
cash EBITDA of approximately USD 49 million, with a current run rate cash EBITDA
at USD 57 million. See further details in the Q4 2023 presentation. 

To assist Aker BioMarine in this process, the Company has engaged Arctic
Securities, Carnegie and Rabobank as financial advisers.



For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.


This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act and contains information deemed to
constitute inside information pursuant to the European Market Abuse Regulation.
This announcement was published by Christopher Robin Vinter, VP IR & Corporate
Finance of Aker BioMarine ASA on 14 February 2024.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange